What is Curiox Biosystems?
Curiox Biosystems, a bioinstrumentation company originating from Singapore's Agency for Science, Technology, and Research (A*STAR), has emerged as a leader in developing and commercializing advanced assay platforms. Leveraging deep expertise in surface chemistry and engineering, Curiox aims to accelerate progress in life sciences, drug discovery, and diagnostics through the miniaturization and automation of bioassays. The company's technological advancements are critical for enhancing efficiency and precision in biological research and clinical applications.
How much funding has Curiox Biosystems raised?
Curiox Biosystems has raised a total of $33.2M across 3 funding rounds:
Series A
$3.2M
Series B
$15M
Series C
$15M
Series A (2010): $3.2M with participation from Zicom Group
Series B (2019): $15M led by DAYLI Investment, QUAD Investment, HB Investment, SV Investment, KB Investment, and IMM Investment
Series C (2022): $15M supported by Luha Private Equity, Quad Investment Management, and KB Investment
Key Investors in Curiox Biosystems
KB Investment
KB Investment is a venture capital and private equity firm based in Seoul, South Korea, established in 1990. It specializes in investing in companies with innovative technology, services, and entrepreneurship, aligning with Curiox's focus on advanced bioinstrumentation.
Quad Investment Management
Quad Investment Management is an investment firm that likely focuses on strategic growth opportunities. Its participation in Curiox's funding round suggests a belief in the company's potential for significant market expansion and technological leadership in the bioinstrumentation sector.
Luha Private Equity
Luha Private Equity is an investment entity that provides capital for companies seeking to scale and enhance their market position. Its involvement indicates a strategic partnership aimed at accelerating Curiox Biosystems' growth and innovation in the life sciences industry.
What's next for Curiox Biosystems?
With its latest major strategic investment, Curiox Biosystems is poised for significant scaling and market penetration. The company's focus on innovation in assay technology, coupled with its strong backing, suggests a strategic push towards expanding its product offerings and global reach. Future developments are likely to center on further enhancing the automation and miniaturization capabilities of its platforms, potentially opening new avenues in personalized medicine and high-throughput screening. This infusion of capital will be instrumental in solidifying Curiox's leadership in the competitive bioinstrumentation landscape.
See full Curiox Biosystems company page
